BioSpace17h
As US Sales of Leqembi Lag, Eisai Eyes SubQ Approvals
The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...
Biogen Stock Down on Regulatory Update in the EU for Alzheimer's Drug
The EC requests CHMP to reassess new safety data that emerged after the positive opinion recommending the approval of ...
Nasdaq4d
Biogen Stock Down on Regulatory Update in the EU for Alzheimer's Drug
Biogen BIIB and Japan-based partner, Eisai, announced an update regarding the regulatory review of an application seeking the approval of Leqembi (lecanemab) for mild cognitive impairment due to ...
Why Are Analysts Bullish on Biogen Inc. (BIIB) Now?
We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going ...
The Pharma Letter4d
BRIEF—EC calls for update on regulatory review of lecanemab
Japan’s Eisai and US partner Biogen have announced today update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab (trade name Leqembi) as a treatment for early ...
Insider Monkey5d
Why Are Analysts Bullish on Biogen Inc. (BIIB) Now?
On January 26, Eisai Co., Ltd. and Biogen announced that the U.S. Food and Drug Administration (FDA) has approved once every four weeks maintenance dosing of Alzheimer’s drug, LEQEMBI.